Skip to main content
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMRX ISIN · US03168L1052 LEI · 549300VV176ZO5WQHZ61 US Manufacturing
Filings indexed 633 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country US United States of America
Listing US AMRX

About Amneal Pharmaceuticals, Inc.

https://amneal.com/

Amneal Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company that develops, manufactures, and distributes a broad portfolio of essential medicines. The company maintains a robust generics business, with over 280 products, and a growing specialty division focused on branded pharmaceuticals. Key therapeutic areas include oncology, with innovative cancer and supportive care therapies, and central nervous system disorders such as Parkinson's disease. Amneal specializes in developing complex medicines, including first-to-file and first-to-market opportunities, to increase affordable access for patients. Additionally, its AvKARE segment distributes pharmaceuticals to U.S. federal government, retail, and institutional markets.

Recent filings

Filing Released Lang Actions
8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
Regulatory Filings
2026-04-22 English
SCHEDULE 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
Major Shareholding Notification
2026-03-26 English
SCHEDULE 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
Major Shareholding Notification
2026-03-26 English
DEFA14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
Regulatory Filings
2026-03-25 English
DEF 14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
Proxy Solicitation & Information Statement
2026-03-25 English
4 - AMNEAL PHARMACEUTICALS, INC. (0001723128) (Filer)
Director's Dealing
2026-03-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.